Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer

Fig. 4

RC48 and CM cooperatively suppressed the cell motility of OC cells. A, B A2780 and OVCAR-3 cells were exposed to VEH, 4 μg/mL RC48, 2.5 μM CM, or COM for 48 h. Cell motility was detected using transwell migration (A, B) and invasion (C, D) assays. Images were captured at 100 × magnification (A, B), with scale bars = 100 µm. E–F A2780 and OVCAR-3 cells were exposed to different treatments for 60 h, including 4 μg/mL RC48, 2.5 μM CM, or COM. Western blotting was performed to examine the expression of EMT markers (ZEB1, N-cadherin, and Snai1). β-tubulin served as the loading control. G A2780 and OVCAR-3 cells were treated with 4 μg/mL RC48, 2.5 μM CM, or COM for 48 h. Representative immunofluorescence images of N-cadherin and E-cadherin in A2780 and OVCAR-3 cells were captured using LSCM at 400 × magnification. Scale bars = 20 µm. Nuclei were counterstained with DAPI. The data shown represent the mean ± SEM from three independent experiments performed in triplicate. Statistically significant values of *p < 0.05, **p < 0.01, and ***p < 0.001

Back to article page